EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
We are delighted to announce EORTC’s participation at the ESTRO Congress 2024 taking place from 3 to 7 May 2024 in Glasgow, UK. This year’s theme is Radiation Oncology: Bridging the Care Gap.
Save the date for the ESTRO-EORTC joint session on innovations in re-irradiation clinical trial design on Saturday 4 May 2024, from 08:45 to 10:00 AM.
In addition to the joint session, we are proud to showcase five abstracts on the topic of radiation oncology: three oral presentations and two digital posters. For a detailed overview, please consult the table below.
ESTRO-EORTC Joint Session
| Session | Scheduled on |
|---|---|
| ESTRO-EORTC – Innovations in re-irradiation clinical trial design Session Type: Interdisciplinary Session code: 1080 |
Saturday 04 May 08:45 – 10:00 GMT+1 Hall 2 |
EORTC Abstracts
| Abstract | Scheduled on |
|---|---|
| Pattern-of-Care Analysis for Radiotherapy of Cutaneous Lymphomas among the European Organisation for Research and Treatment of Cancer (EORTC) Khaled Elsayad, Germany Session Type: Proffered Papers |
Saturday 04 May 10:30 – 11:30 GMT+1 Clyde |
| Interim results of the prospective RTQA procedures for HALT (CRUK/16/020, EORTC 1702-LCG-ROG) Daniel Portik, EORTC HQ Session Type: Proffered Papers |
Saturday 04 May 17:00 – 18:00 GMT+1 Hall 3 |
| Early Quality-of-Life after metastases-directed SBRT – results of the ESTRO & EORTC OligoCare cohort* Daniela Greto, Italy Session Type: Proffered paper |
Saturday 04 May 17:00 – 18:00 GMT+1 Hall 2 |
| Head-to-head comparison for breast RT planning: knowledge-based planning vs. deep learning solution Daniel Portik, EORTC HQ |
Digital Poster |
| A Trials within Cohorts comparing 1 fraction vs multiple-fraction SBRT in oligometastatic cancer* Piet Ost, Belgium |
Digital Poster |
*The Oligocare project is part of the E²-RADIatE platform. The E²-RADIatE platform and Oligocare project are supported by Walgreens Boots Alliance. OligoCare is also supported by Stiftung Bruckner.
Related News
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
